stoxline Quote Chart Rank Option Currency Glossary
Immix Biopharma, Inc. (IMMX)
4.8  -0.19 (-3.81%)    12-08 16:00
Open: 5.02
High: 5.02
Volume: 144,140
Pre. Close: 4.99
Low: 4.6657
Market Cap: 94(M)
Technical analysis
2023-12-08 4:44:03 PM
Short term     
Mid term     
Targets 6-month :  6.38 1-year :  7.46
Resists First :  5.46 Second :  6.38
Pivot price 4.84
Supports First :  4.17 Second :  3.38
MAs MA(5) :  4.98 MA(20) :  4.72
MA(100) :  3.16 MA(250) :  2.56
MACD MACD :  0.3 Signal :  0.3
%K %D K(14,3) :  60.4 D(3) :  66.6
RSI RSI(14): 55.7
52-week High :  5.46 Low :  1.28
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ IMMX ] has closed above bottom band by 46.5%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.03 - 5.06 5.06 - 5.08
Low: 4.6 - 4.63 4.63 - 4.66
Close: 4.75 - 4.8 4.8 - 4.84
Company Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Headline News

Thu, 30 Nov 2023
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit - Yahoo Finance

Wed, 29 Nov 2023
Is Immix Biopharma Inc (IMMX) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver

Tue, 28 Nov 2023
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St

Tue, 28 Nov 2023
Should You Buy Immix Biopharma Inc (IMMX) Stock on Tuesday? - InvestorsObserver

Tue, 28 Nov 2023
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' - Yahoo Finance

Fri, 24 Nov 2023
Pleasing Signs As A Number Of Insiders Buy Immix Biopharma Stock - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 20 (M)
Shares Float 8 (M)
Held by Insiders 53.4 (%)
Held by Institutions 2.2 (%)
Shares Short 243 (K)
Shares Short P.Month 172 (K)
Stock Financials
EPS -0.93
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -45.7 %
Return on Equity (ttm) -78.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.74
Qtrly Earnings Growth 0 %
Operating Cash Flow -13 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -5.22
PEG Ratio 0
Price to Book value 4.75
Price to Sales 0
Price to Cash Flow -7.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android